In a unanimous ruling on January 12, 2026, Delaware’s Supreme Court set aside a key finding in a September 2024 judgment that had awarded more than $1 billion in damages to former Auris Health shareholders. The court found that the merger agreement did not impose an implied obligation on J&J to secure regulatory approval for Auris’s iPlatform by the end of 2021. While upholding most breach-of-contract and fraud findings, the decision remands the case to the Chancery Court for a recalculation of damages, potentially reducing J&J’s liability by a few hundred million dollars. This follows J&J’s 2019 acquisition of Auris Health for approximately $3.4 billion in cash, plus up to $2.35 billion in contingent payments tied to regulatory and commercial milestones. Investors should weigh the possible one-time reduction in contingent liabilities against ongoing legal and integration costs related to the acquisition.

At the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held January 12–15 in Nassau, Bahamas, J&J presented 11 abstracts showcasing Phase 3 and preclinical data across major depressive disorder (MDD), treatment-resistant depression (TRD) and schizophrenia. Key presentations included remission rates for CAPLYTA® (lumateperone) adjunctive therapy, post-hoc analyses of esketamine nasal spray (SPRAVATO®) on anhedonia, and comparative tolerability of the investigational orexin-2 receptor antagonist seltorexant versus quetiapine XR in MDD patients with insomnia symptoms. With MDD affecting an estimated 332 million people globally and treatment-resistant cases representing roughly one-third of that population, J&J’s expanded neuropsychiatry portfolio underscores its commitment to high-growth CNS markets and could drive future revenue streams as these products advance toward regulatory filings.